Role of adenosine in the heart and circulation

Cardiovascular Research

Volumn 32, Issue 5, 1996, Pages 797-813

  Mubagwa, K ^a   Mullane, K ^b   Flameng, W ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Gensia Inc   (United States)

Author keywords

adenosine receptor; arrhythmia; ion channel; metabolism; myocardial protection; vasodilation

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR;

HEART; HEART ARRHYTHMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASODILATATION;

ADENOSINE; CARDIOVASCULAR DISEASES; CORONARY CIRCULATION; HEART; HUMANS;

EID: 0030297184     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00140-X     Document Type: Review

References (191)

1. [1] Hori M, Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension 1991;18:565-74.
2. [2] Drury AN, Szent-Gyšrgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol (Lond) 1929;68:213-37.
3. [3] Pelleg A, Hurt CM, Michelson EL. Cardiac effects of adenosine and ATP. Ann NY Acad Sci 1990;603:19-30.
4. [4] Belardinelli L, Lerman BB. Adenosine: Cardiac electrophysiology. Pace 1991;14:1672-80.
5. [5] Berne RM. Cardiac nucleotides in hypoxia: Possible role in regulation of coronary blood flow. Am J Physiol 1963;204:317-22.
6. [6] Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992;85:893-904.
7. [7] Clarke B, Coupe M. Adenosine: Cellular mechanisms, pathophysiological roles and clinical applications. Int J Cardiol 1989;23:1-10.
8. [8] Ohisalo JJ. Regulatory functions of adenosine. Med Biol 1987;65:181-91.
9. [9] Bing RJ, Hammond MM, Handelsman JC, et al. The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man. Am Heart J 1949;38:1-24.
10. [10] Berne RM. Regulation of coronary blood flow. Physiol Rev 1964;44:1-29.
11. [11] Bache RJ, Dymek DJ. Local and regional regulation of coronary vascular tone. Prog Cardiovasc Dis 1981;24:191-212.
12. [12] Gellai M, Norton JM, Detar R. Evidence for direct control of coronary vascular tone by oxygen. Circ Res 1973;32:279-89.
13. [13] Nees S. The adenosine hypothesis of metabolic regulation of coronary flow in the light of newly recognized properties of the coronary endothelium. Z Kardiologie 1989;78(Suppl 6): 42-9.
14. [14] Bruns RF. Adenosine receptors - roles and pharmacology. Ann NY Acad Sci 1990;603:211-26.
15. [15] Burnstock G. Vascular conrol by purines with emphasis on the coronary system. Eur Heart J 1989;10(Suppl F):15-21.
16. [16] Rubino A, Burnstock G. Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Cardiovasc Res 1996;31:467-79.
17. [17] Belardinelli L. Adenosine system in the heart. Drug Dev Res 1993;28:263-7.
18. [18] Sparks HV, Bardenheuer H. Regulation of adenosine formation by the heart. Circ Res 1986;58:193-201.
19. [19] Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine - basic and clinical concepts. Circulation 1991;83(Suppl 5): 1499-509.
20. [20] Meghi P, Holmquist CA, Newby AC. Adenosine formation and release from neonatal-rat heart cells in culture. Biochem J 1985;229:799-805.
21. [21] Schütz W, Schrader J, Gerlach E. Different sites of adenosine formation in the heart. Am J Physiol 1981;240:H963-70.
22. [22] Bardenheuer H, Whelton B, Sparks HV Jr. Adenosine release by the isolated guinea pig heart in response to isoproterenol, acetylcholine, and acidosis: The minimal role of vascular endothelium. Circ Res 1987;61:594-600.
23. [23] Itoh R, Oka J, Ozasa H. Regulation of rat heart cytosol 5-nucleotidase by adenylate energy charge. Biochem J 1986;235:847-51.
24. [24] Darvish A, Metting PJ. Purification and regulation of an AMP-specific cytosolic 5′-nucleotidase from dog heart. Am J Physiol 1993;264:H1528-34.
25. 1 receptor activation in the rat cardiomyocytes. J Clin Invest 1994;94:2451-6.
26. 1-adrenoceptor activation increases ecto-5′-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. Circulation 1995;91:2226-34.
27. [27] Gorman MW, He MX, Sparks HV. Adenosine formation during hypoxia in isolated hearts: effect of adrenergic blockade. J Mol Cell Cardiol 1994;26:1613-23.
28. [28] Borst MM, Schrader J. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine. Circ Res 1991;68:797-806.
29. [29] Rubio R, Berne RM. Release of adenosine by the normal myocardium in dogs and its relationship to the regulation of coronary resistance. Circ Res 1969;25:407-15.
30. [30] Lloyd HG, Schrader J. Adenosine metabolism in the guinea pig heart: the role of cytosolic S-adenosyl-L-homocysteine hydrolase, 5′-nucleotidase and adenosine kinase. Eur Heart J 1993;14(Suppl I):27-33.
31. [31] Zimmer H-G, Trendelenburg C, Kammermeier H, Gerlach E. De novo synthesis of myocardial adenine nucleotides in the rat. Acceleration during recovery from oxygen deficiency. Circ Res 1973;32:635-42,
32. [32] Manfredi JP, Holmes EW. Purine salvage pathways in myocardium. Annu Rev Physiol 1985;47:691-705.
33. [33] Klabunde RE. Dipyradimole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1983;93:21-6.
34. [34] Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc Res 1993;27:68-76.
35. [35] Lasley RD, Ely SW, Berne RM, Mentzer RM Jr. Auopurinol enhanced adenine .nucleotide repletion after myocardial ischemia in the isolated rat heart. J Clin Invest 1988;81:16-20.
36. [36] Olsson RA. Changes in content of purine nucleoside in canine myocardium during coronary occlusion. Circ Res 1970;26:301-6.
37. [37] Rubio R, Widmeier VT, Berne RM. Relationship between coronary flow and adenosine production and release. J Mol Cell Cardiol 1974;6:561-6.
38. [38] Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989;32:73-97.
39. [39] Foley DH, Herlihy JT, Thompson CI, Rubio R, Berne RM. Increased adenosine formation by rat myocardium with acute aortic constriction. J Mol Cell Cardiol 1978;10:293-300.
40. [40] Ely SW, Knabb RM, Bacchus AN, Rubio R, Berne RM. Measurements of coronary plasma and pericardial infusate adenosine concentrations during exercise in conscious dog: relationship to myocardial oxygen consumption and coronary blood flow. J Mol Cell Cardiol 1983;15:673-83.
41. [41] Berne RM. The role of adenosine in the regulation of coronary blood How. Circ Res 1980;47:807-13.
42. [42] Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990;70:761-845.
43. [43] Olah ME, Stiles GL. Adenosine receptors. Annu Rev Physiol 1992;54:211-25.
44. [44] Gurden MF, Coates J, Ellis F, et at. Functional characterization of three adenosine receptor types. Br J Pharmacol 1993;109:693-8.
45. [45] Linden J, Tucker AL, Robeva AS, Graber SG, Munshi R. Properties of recombinant adenosine receptors. Drug Dev Res 1993;28:232-6.
46. 3) adenosine receptor. Prog Neurobiol 1986;26:179-209.
47. [47] Gustafsson LE, Wiklund CU, Wiklund NP, Stelius L. Subclassification of neuronal adenosine receptors. In: Jacobson KA, Daly JW, Manganiello V, eds. Purines in Cellular Signaling: Targets for New Drugs. Berlin: Springer-Verlag, 1990;200-5.
48. 3 adenosine receptor. Proc Natl Acad Sci USA 1992;89:7432-6.
49. 3H]CV1808) labels a novel adenosine receptor in rat brain. J Pharmacol Exp Ther 1992;263:552-61.
50. 1-adenosine receptors in embryonic chicken heart. Am J Physiol 1989;256:H321-7.
51. [51] Lee HT, Thompson CI, Hernandez A, Lewy JL, Belloni FL. Cardiac desensitization to adenosine analogues after prolonged R-P1A infusion in vivo. Am J Physiol 1993;265:H1916-27.
52. [52] Wu S-N, Linden J, Visentin S, Boykin M, Belardinelli L. Enhanced sensitivity of heart cells to adenosine and up-regulation of receptor number after treatment of guinea pigs with theophylline. Circ Res 1989;65:1066-77.
53. [53] Pappano AJ, Mubagwa K. Actions of muscarinic agents and adenosine on the heart. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System. Scientific Foundations. VoL 2. 2nd edition. New York: Raven Press, 1992;1765-76.
54. [54] Marsch SCU. Adenosine. Ballieres Clin Anaesthesiol 1994;8:201-14.
55. [55] Shen WK, Kurachi Y. Mechanisms of adenosine-mediated actions on cellular and clinical cardiac electrophysiology. Mayo Clin Proc 1995;70:274-91.
56. 1 stimulation activates δ-protein kinase C in rat ventricular myocytes. Circ Res 1996;78:161-5.
57. 3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol 1993;109:3-5.
58. [58] Belardinelli L, Shryock JC, Song Y, Wang D, Srinivas M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J 1995;9:359-65.
59. [59] Dobson JG. Reduction by adenosine of the isoproterenol induced increase in cyclic adenosine 3′,5′-monophosphate formation and glycogen phosphorylase activity in rat heart muscle. Circ Res 1978;43:785-92.
60. 1 receptors by G proteins in rat ventricular myocytes. Am J Physiol 1990;259:H820-6.
61. [61] Ito H, Vereecke J, Carmeliet E. Mode of regulation by G protein of the ATP-sensitive channel in guinea-pig ventricular cell membrane. J Physiol (Lond) 1994;478:101-8.
62. ATP channel. Am J Physiol 1994;266:H829-39.
63. [63] Parratt JR. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci 1994;15:19-25.
64. [64] George EE, Romano FD, Dobson JG Jr. Adenosine and acetylcholine reduce isoproterenol-induced protein phosphorylation of rat myocytes. J Mol Cell Cardiol 1991;23:749-64.
65. [65] Lasley RD, Rhee JW, Van Wylen DGL, Mentzer RM. Adenosine A, receptor mediated protection of the globally ischemic isolated rat heart. J Mol Cell Cardiol 1990;22:39-47.
66. 1-adenosine receptors. Am J Physiol 1989;257:H1952-7.
67. [67] van Buren M, Bijlsma JA, Boer P, Van Rijn HJM, Koomans HA. Natriuretic and hypotensive effect of adenosine-1 blockade in essential hypertension. Hypertension 1993;22:728-34.
68. 1 Tóth M, Hassinen IE, Peuhkurinen KJ, Ruskoaho H. Adenosine inhibits the release of atrial natriuretic peptide from the perfused rat heart. Eur J Pharmacol 1993;242:199-203.
69. [69] Jackson EK. Adenosine: A physiological brake on renin release. Annu Rev Pharmacol Toxicol 1991;31:1-35.
70. [70] Silver PJ, Walus K, DiSalvo J. Adenosine-mediated relaxation and activation of cyclic AMP-dependent protein kinase in coronary arterial smooth muscle. J Pharmacol Exp Ther 1984;228:342-7.
71. [71] Gatell JA, Barner HB, Shevde K. Adenosine and myocardial protection. J Cardtothor Vase Anesth 1993;7:466-80.
72. [72] Cronstein BN, Levin RI, Belanoff J, et al. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;78:760-70.
73. [73] Roberts PA, Newby AC, Hallett MB, Campbell AK. Inhibition by adenosine of reactive oxygen metabolite production by human polymorphonuclear leucocytes. Biochem J 1985;227:669-79.
74. [74] Cusak NJ, Hourain SMO. 5′-N-ethylcarboxamideadenosine: a potent inhibitor of human platelet aggregation. Br J Pharmacol 1981;72:443-7.
75. [75] Kitakaze M, Hori M, Sato H, et al. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs. Circ Res 1991;69:1402-8.
76. 2b receptors in cultured fetal chick heart cells: high- and low-affinity coupling to stimulation of myocyte contractility and cAMP accumulation. Circ Res 1995;76:242-51.
77. [77] Scholz H, Kohl C, Neumann J, Schmitz W, Seeland C, Stein B. Inotropic action of adenosine derivatives in the mammalian heart. Drug Dev Res 1993;28:277-82.
78. 2-adenosine receptors in guinea-pig ventricular cardiomyocytes. J Mol Cell Cardiol 1994;26:403-14.
79. [79] Belardinelli L, Pelleg A. Cardiac electrophysiology and pharmacology of adenosine. J Cardiovasc Electrophysiol 1990;1:327-39.
80. [80] Martynyuk AE, Kane KA, Cobbe SM, Rankin AG. Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes. Cardiovasc Res 1995;30:668-75.
81. + channels in mammalian ventricular myocytes. Am J Physiol 1994;266:H1812-21.
82. + channel in ferret ventricular myoctyes. Naunyn-Schmiedeberg's Arch Pharmacol 1995;351:610-7.
83. [83] Xu J, Wang L, Hurt CM, Pelleg A. Endogenous adenosine does not activate ATP-sensitive potassium channels in the hypoxic guinea pig ventricle in vivo. Circulation 1994;89:1209-16.
84. [84] Song Y, Thedford S, Lerman BB, Belardinelli L. Adenosine-sensitive after depolarizations and triggered activity in guinea pig ventricular myocytes. Circ Res 1992;70:743-53.
85. [85] Schrader J, Baumann G, Gerlach E. Adenosine as inhibitor of myocardial effects of catecholamines. Pflügers Arch 1977;372:29-35.
86. [86] Kumar R, Akita T, Joyner RW. Adenosine and carbachol are not equivalent in their effects on L-type calcium current in rabbit ventricular cells. J Mol Cell Cardiol 1996;28:403-15.
87. 2-purinoceptor-mediated relaxation in the guinea-pig coronary vasculature: a role for nitric oxide. Br J Pharmacol 1993;109:424-9.
88. [88] Zanzinger J, Bassenge E. Coronary vasodilation to acetylcholine, adenosine and bradykinin in dogs: effects of inhibition of NO-synthesis and captopril. Eur Heart J 1993;14(Suppl I):164-8.
89. [89] Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, GŸnther K, Goedel-Meinen L. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990;247:1341-4.
90. [90] Belloni FL, Hintze TH. Glibenclamide attenuates adenosine-induced bradycardia and coronary vasodilatation. Am J Physiol 1991;261:H720-7.
91. 2 receptor-mediated vasodepression does not involve a pertussis toxin-sensitive G protein. Eur J Pharmacol 1993;236:255-62.
92. + channel activation. Am J Physiol 1993;265:H34.
93. [93] Niiya K, Uchida S, Tsuji T, Olsson RA. Glibenclamide reduces the coronary vasoactivity of adenosine receptor agonists. J Pharmacol Exp Ther 1994;271:14-9.
94. 2 receptor agonists in the pithed rat: No role for glibenclamide-sensitive potassium channels. Naunyn-Schmiedeberg's Arch Pharmacol 1993;347:192-6.
95. [95] Rovetto MJ, Whitmer JT, Neely JR. Comparison of the effects of anoxia and whole heart ischemia on carbohydrate utilization in isolated working rat hearts. Circ Res 1973;32:699-711.
96. [96] Lasley RD, Mentzer RM Jr. Adenosine increases lactate release and delays onset of contracture during global low flow ischaemia. Cardiovasc Res 1993;27:96-101.
97. [97] Berne RM. Adenosine - a cardioprotective and therapeutic agent. Cardiovasc Res 1993;27:2.
98. [98] Vander Heide RS, Reimer KA, Jennings RB. Adenosine slows ischaemic metabolism in canine myocardium in vitro: relationship to ischaemic preconditioning. Cardiovasc Res 1993;27:669-73.
99. [99] Yokota R, Fujiwara H, Miyamae M, et al. Transient adenosine infusion before ischemia and reperfusion protects against metabolic damage in pig hearts. Am J Physiol 1995;268:H1149-57.
100. [100] Richardt G, Waas W, Kranzhöfer R, Mayer E, Schömig A, Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: A protective mechanism in early myocardial ischemia. Circ Res 1987;61:117-23.
101. [101] Bardenheuer H, Schrader J. Supply-to-demand ratio for oxygen determines formation of adenosine by the heart. Am J Physiol 1986;250:H173-80.
102. [102] DiMarco JP, Sellers TD, Berne RM, West GA, Belardinelli L. Adenosine: Electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983;68:1254-63.
103. 1 adenosine receptors in atrial and ventricular myocardium from diseased human hearts. Circ Res 1989;65:1201-11.
104. 1 adenosine receptors in human myocardium. Am J Physiol 1994;266:H1951-8.
105. [105] Norton DE, Jackson KE, Virmani R, Forman MB. Effect of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J 1991;122:1283-91.
106. [106] Rubanyi GM, Vanhoutte PM. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J Physiol (Lond) 1985;364:45-56.
107. [107] Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: Evidence for a central mechanism of free radical injury in post-ischemic tissues. Proc Natl Acad Sci USA 1988;85:4046-50.
108. [108] Lefer AM, Tsao PS, Lefer DJ, Ma X-L. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J 1991;5:2029-34.
109. 1 receptor activation attenuates cardiac injury produced by hydrogen peroxide. Circ Res 1992;71:1101-10.
110. [110] Engler RL, Dahlgren MD, Peterson MA, Dobbs A, Schmid-Schönbein GW. Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia. Am J Physiol 1986;251:H93-100.
111. [111] Sheridan FM, Dauber IM, McMurtry IF, Lesnefsky EJ, Horwitz LD. Role of leukocytes in coronary vascular endothelial injury due to ischemia and reperfusion, Circ Res 1991;69:1566-74.
112. 2 generation, respectively. J Clin invest 1990;85:1150-7.
113. [113] Kitakaze M, Hori M, Sato H, Takashima S, Kitabatake A. Endogenous adenosine inhibits formation of microthromboembolism in ischemic myocardium. Circulation 1990;82(Suppl): 111-276.
114. [114] Adair TH, Gay WJ, Montani J-P. Growth regulation of the vascular system: Evidence for a metabolic hypothesis. Am J Physiol 1990;259:R393-404.
115. [115] Meininger CJ, Schelling ME, Granger HJ. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. Am J Physiol 1988;255:H554-62.
116. [116] Mattfeldt T, Mall G. Dipyridamole-induced capillary endothelial cell proliferation in the rat heart: a morphometric investigation. Cardiovasc Res 1983;17:229-37.
117. [117] Malcolm AD, Garratt CJ, Camm AJ. The therapeutic and diagnostic cardiac electrophysiological uses of adenosine. Cardiovasc Drugs Ther 1993;7:139-47.
118. [118] Mosqueda-Garcia R. Adenosine as a therapeutic agent. Clin Invest Med 1992;15:445-55.
119. [119] Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med 1992;92:655-64.
120. [120] Domanovits H, Laske H, Stark G, et al. Adenosine for the management of patients with tachycardias - a new protocol. Eur Heart J 1994;15:589-93.
121. [121] Kall JG, Kopp D, Olshansky B, Kinder C, O'Connor M, Cadman CS, Wilber D. Adenosine-sensitive atrial tachycardia. Pacing Clin Electrophysiol 1995;18:300-6.
122. [122] DiMarco J, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: Dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. Ann Intern Med 1990;113:104-10.
123. [123] Griffith MJ, Garratt CJ, Ward DE, et al. The effects of adenosine on sinus node re-entrant tachycardia. Clin Cardiol 1989;12:409-11.
124. [124] Stark G, Sterz F, Stark U, et al. Effects of adenosine on electrical activity of isolated guinea pig hearts. Basic Res Cardiol 1993;88:23-32.
125. [125] Lerman BB, Belardinelli L, West GA, Berne RM, DiMarco JP. Adenosine-sensitive ventricular tachycardia: Evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986;74:270-80.
126. [126] Braunwald E, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation 1982;66:1146-9.
127. [127] Ito BR, Libraty DH, Engler RL. Effect of transient coronary occlusion on coronary blood flow autoregulation, vasodilator reserve and response to adenosine in the dog. J Am Coll Cardiol 1991;18:858-67.
128. [128] Miura T, Iimura O. Infarct size limitation by preconditioning: Its phenomenological features and the key role of adenosine. Cardiovasc Res 1993;27:36-42.
129. 2 receptors prevent myocardial stunning. Circulation 1990;82(Suppl):III-37.
130. [130] Velasco CE, Turner M, Cobb A, Virmani R, Forman MB. Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: Effect of intracoronary adenosine. Am Heart J 1991;122:1561-70.
131. [131] Pitarys CJ, Virmani R, Vildibill HD, Jackson EK, Forman M. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 1991;83:237-47.
132. [132] Babbitt DG, Virmani R, Vildibill HD, Norton ED, Forman MB. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: Effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J 1990;120:808-18.
133. 1 adenosine receptors in rabbit heart. Circulation 1991;84:350-6.
134. [134] Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res 1993;27:3-8.
135. [135] Urabe K, Miura T, Iwamoto T, Ogawa T, Goto M, Sakamoto J, Iimura O. Preconditioning enhances myocardial resistance to postischaemic myocardial stunning via adenosine receptor activation. Cardiovasc Res 1993;27:657-62.
136. [136] Lasley RD, Anderson GM, Mentzer RM Jr. Ischaemic and hypoxic preconditioning enhance postischaemic recovery of function in the rat heart. Cardiovasc Res 1993;27:565-70.
137. [137] Sekili S, Jeroudi MO, Tang XL, Zughaib M, Sun JZ, BoIH R. Effect of adenosine on myocardial 'stunning' in the dog. Circ Res 1995;76:82-94.
138. [138] Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation 1994;90:2993-3000.
139. [139] Thornton J, Downey J. Blocking adenosine receptors between preconditioning and prolonged ischemia prevents protection. Circulation 1992;86(Suppl):I-343.
140. + Channels in Cardiovascular Medicine: From Gene to Patient. New York: Springer-Verlag.
141. ATP channels, and ischemic preconditioning in dogs. Am J Physiol 1993;264:H1327-36.
142. [142] Armstrong S, Downey JM, Ganote CE. Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor. Cardiovasc Res 1994;28:72-7.
143. 1 receptor activation. Basic Res Cardiol 1993;88:579-93.
144. [144] Asimakis GK, Inners-McBride K, Conti VR. Attenuation of postischaemic dysfunction by ischaemic preconditioning is not mediated by adenosine in the isolated rat heart. Cardiovasc Res 1993;27:1522-30.
145. [145] Cave AC, Collis CS, Downey JM, Hearse DJ. Improved functional recovery by ischaemic preconditioning is not mediated by adenosine in the globally ischaemic isolated rat heart. Cardiovasc Res 1993;27:663-8.
146. [146] Li Y, Kloner RA. The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts. Circulation 1993;87:1642-8.
147. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28:1057-61.
148. [148] Homeister JW, Hoff PT, Fletcher DD, Lucchesi BR. Combined adenosine and Iidocaine administration limits myocardial reperfusion injury. Circulation 1990;82;595-608.
149. [149] Wyatt DA, Ely SW, Lastey RD, et al. Purine-enriched asanguineous cardioplegia retards adenosine triphosphate degradation during ischemia and improves postischemic ventricular function. J Thorac Cardiovasc Surg 1989;97:771-8.
150. [150] Schubert T, Vetter H, Owen P, Reichart B, Opie LH. Adenosine cardioplegia. Adenosine versus potassium cardioplegia: Effects on cardiac arrest and postischemic recovery in the isolated rat heart. J Thorac Cardiovasc Surg 1989;98:1057-65.
151. [151] de Jong WJ, van der Meer P, van Loon H, et al. Adenosine as an adjunct to potassium cardioplegia: Effect on function energy metabolism and electrophysiology. J Cardiovasc Surg 1990;100:445-54.
152. [152] Ledingham S, Katayama O, Lachno D, et al. Beneficial effect of adenosine during reperfusion following prolonged cardioplegic arrest. Cardiovasc Res 1990;24:247-53.
153. [153] Petsikas D, Rocci MA, Baffour R, deVarennes B, Symes J, Guerraty A. Enhanced 24-hour in vitro heart preservation with adenosine and adenosine monophosphate. J Heart Transplant 1990;9:114-8.
154. [154] Malhotra D, Zhou HZ, Kong YL, Shapiro JI, Chan L. Improvement in experimental cardiac preservation based on metabolic considerations. Transplantation 1991;52:1004-8.
155. [155] Petsikas D, Mohamed F, Ricci M, et al. Adenosine enhances left ventricular flow during 24-hour hypothermie perfusion of isolated cardiac allografts. J Heart Transplant 1990;9:543-7.
156. [156] Stein DG, Drinkwater DC Jr, Laks H, et al. Cardiac preservation in patients undergoing transplantation. A clinical trial comparing University of Wisconsin solution and Stanford solution. J Thorac Cardiovasc Surg 1991;102:657-65.
157. [157] Bloor BC, Fukunaga AF, Ma C, et al. Myocardial hemodynamics during induced hypotension: A comparison between sodium nitroprusside and adenosine triphosphate. Anesthesiology 1985;63:517-25.
158. [158] Lagerkranser M, Sollevi A, Irestedt L, et al. Renin release during controlled hypotension with sodium nitroprusside, nitroglycerin and adenosine: A comparative study in the dog. Acta Anaesth Scand 1985;29:45-9.
159. [159] Biaggioni I, Olafsson B, Robertson RM, Hollister AS, Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man: Evidence of chemoreceptor activation. Circ Res 1987;61:779-86.
160. [160] Sollevi A, Lagerkranser M, Irestedt L, et al. Controlled hypotension with adenosine in cerebral aneurysm surgery. Anesthesiology 1984;61:400-5.
161. [161] Öwall A, Sollevi A. Myocardial effects of adenosine- and sodium nitroprusside-induced hypotension: a comparative study in patients anaesthetized for abdominal aortic aneurysm surgery. Acta Anaesth Scand 1991;35:216-20.
162. [162] Zäll S, Miloco I, Ricksten S-E. Effects of adenosine on renal function and central hemodynamics after coronary artery bypass surgery. Anesth Analg 1993;76:493-7.
163. [163] Morgan JM, McCormack DG, Griffiths MJD, et al. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991;84:1145-9.
164. [164] Schrader BJ, Inbar S, Kaufmann L, et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;19:1060-4.
165. [165] Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995;107:54-7.
166. [166] Verani MS, Mahmarian JJ, Hixson JB, et al. Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to undergo exercise. Circulation 1990;82:80-7.
167. [167] Coyne EP, Belvedere DA, Vande Streck PR, et al. Thallium-201 scintigraphy after intravenous infusion of adenosine compared with exercise thallium testing in the diagnosis of coronary artery disease. J Am Coll Cardiol 1991;17:1289-94.
168. [168] Gupta NC, Esterbrooks DJ, Hilleman DE, Mohiuddin SM. Comparison of adenosine and exercise thallium-201 single-proton emission computed tomography (SPECT) myocardial perfusion imaging. J Am Coll Cardiol 1992;19:248-57.
169. [169] Rankin AC. Oldroyd KG, Chong E, et al. Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br Heart J 1989;62:195-203.
170. [170] Ilkhanipour K, Berrol R, Yealy DM. Therapeutic and diagnostic efficacy of adenosine in wide-complex tachycardia. Ann Emerg Med 1993;22:1360-4,
171. [171] Garratt CJ, Antoniou A, Griffith MJ, et al. Use of intravenous adenosine in sinus rhythm as a diagnostic test for latent preexcitation. Am J Cardiol 1990;65:868-73.
172. [172] Crea F, Pupita G, Galassi AR, et al. Role of adenosine in pathogenesis of anginal pain. Circulation 1990;81:164-72.
173. [173] Sylvén C. Mechanisms of pain in angina pectoris - a critical review of the adenosine hypothesis. Cardiovasc Drugs Ther 1993;7:745-59.
174. [174] Lerman BB, Engelstein ED. Metabolic determinants of defibrillation. Role of adenosine. Circulation 1995;91:838-44.
175. [175] Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res 1993;27:43-7.
176. [176] Leung J, Stanley T, Mathew J, et al. Effects of acadesine on perioperative cardiac morbidity in a placebo-controlled, double-blind study. J Am Coll Cardiol 1992;19:112A.
177. [177] Hori M, Kitakaze M, Takashima S, et al. AICA riboside improves myocardial ischemia in coronary microembolization in dogs. Am J Physiol 1994;267:H1483-95.
178. [178] Tsuchida A, Liu GS, Mullane K, Downey JM. Acadesine lowers temporal threshold for the myocardial infarct size limiting effect of preconditioning. Cardiovasc Res 1993;27:116-20.
179. [179] Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Anesthesiology 1995;83:658-73.
180. [180] Menasché P, Jamieson WR, Flameng W, Davies MK. Acadesine: a new drug may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational acadesine study group. J Thorac Cardiovasc Surg 1995;110:1096-106.
181. [181] Kollias-Baker C, Ruble J, Dennis D, Bruns RF, Linden J, Belardinetli L. Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ Res 1994;75:961-71.
182. [182] Flameng W, Daenen W, Borgers M, Thoné F, Xhonneux R, Van de Water A, Van Belle H. Cardioprotective effects of lidoflazine during 1-hour normothermic global ischemia. Circulation 1981;64:796-807.
183. [183] Flameng W, Borgers M, Van der Vusse GJ, et al. Cardioprotective effects of lidoflazine in extensive aorto-coronary bypass grafting. J Thorac Cardiovasc Surg 1983;85:758-68.
184. [184] Chang-Chun C, Masuda M, Szabb Z, Szerafm T, Scecsi J, Van Belle H, Flameng W. Nucleoside transport inhibition mediates lidoflazine-induced cardioprotection during intermittent aortic crossclamping. J Thorac Cardiovasc Surg 1992;104:1602-9.
185. [185] Flameng W, Xhonneux R, Van Belle H, et al. Cardioprotective effects of mioflazine during 1h normothermic global ischaemia in the canine heart. Cardiovasc Res 1984;18:528-37.
186. [186] Masuda M, Sukehiro S, Möllhoff T, Van Belle H, Flameng W. Effect of nucleoside transport inhibition on adenosine and hypoxanthine accumulation in the ischemic human myocardium. Arch Int Phamiacodyn Thér 1993;322:45-54.
187. [187] Masuda M, Demeulenmeester A, Chen CC, Hendrikx M, Van Belle H, Flameng W. Cardioprotective effects of nucleoside transport inhibition in rabbit hearts. Ann Thorac Surg 1991;52:1300-5.
188. [188] Masuda M, Chang-Chun C, Möllhoff T, Van Belle H, Flameng W. Effects of nucleoside transport inhibition on long-term ex vivo preservation of canine hearts. J Thorac Cardiovasc Surg 1992;104:1610-7.
189. [189] Itoya M, Miura T, Sakamoto J, Urabe K, Iimura O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovasc Pharmacol 1994;24:846-52.
190. [190] Fremes SE, Furukawa RD, Zhang J, Li RK, Tumiati LC, Weisel RD, Mickle DA. Cardiac storage with University of Wisconsin solution and a nucleoside-transport blocker. Ann Thorac Surg 1995;59:1127-33.
191. [191] Abd-Elfattah AS, Wechsler AS. Separation between ischemic and reperfusion injury by site specific entrapment of endogenous adenosine and inosine using NBMPR and EHNA. J Card Surg 1994;9(Suppl):387-96.